Bram Wouterse,Joao Vasco Santos,Mickaël Hiligsmann
Bram Wouterse
Won Chan Lee,Chris Blanchette,Shibani Pokras et al.
Won Chan Lee et al.
Introduction: Integrated Evidence Planning (IEP) is a strategic approach that optimizes drug development by ensuring evidence generation aligns with regulatory, clinical, and market needs. The increasing integration of ad...
Access to medicines, care, and services for multiple sclerosis patients in central and eastern European countries: a comparative analysis [0.03%]
中欧和东欧国家多发性硬化症患者的医药、护理及服务可及性的比较分析
Yoana Seitaridou,Dominik Grega,Sorin Paveliu et al.
Yoana Seitaridou et al.
Background: The study compared access to disease-modifying treatments (DMTs), care, and services for multiple sclerosis (MS) patients across six Central and Eastern European Countries (CEECs). ...
Consumption and expenditure of drugs used for the treatment of hypercholesterolemia: a governance analysis [0.03%]
高胆固醇治疗药物的消费和支出治理分析
Francesco Ferrara,Andrea Zovi,Roberto Langella et al.
Francesco Ferrara et al.
Background: Elevated cholesterol levels are a significant contributor to cardiovascular disease risk. While statins have long been the cornerstone for lowering LDL cholesterol, their associated side effects have prompted ...
Cardiovascular events, mortality, and incident type 2 diabetes in patients with metabolic dysfunction-associated steatohepatitis: a claims-based analysis of commercial and medicare advantage enrollees [0.03%]
代谢功能紊乱相关非酒精性脂肪肝病患者的临床结局：商保及 Medicare 优势计划参保人资料的分析
Semiu O Gbadamosi,Jason P Swindle,Hai Nguyen et al.
Semiu O Gbadamosi et al.
Background: The objective of this study was to examine the risks of cardiovascular events, incident type 2 diabetes (T2D), and mortality in patients with newly diagnosed metabolic dysfunction - associated steatohepatitis ...
New drug accessibility and budgetary impact in South Korea: policy challenges and implications [0.03%]
韩国新药的可及性和预算影响：政策挑战与含义
Se-Eun Hwang,Yoon-A Jang,Kyung-Min Lim et al.
Se-Eun Hwang et al.
Background: To compare the accessibility indicators for new drugs in South Korea with those in the United States, Europe, and Japan, and examine the structure of pharmaceutical expenditures in South Korea. ...
Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China [0.03%]
在中国广泛期小细胞肺癌患者中添加替雷利珠单抗作为一线化疗的综合经济价值评估
Shan Zhao,Shuo Kang
Shan Zhao
Background: The cost-effectiveness of tislelizumab plus chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC) was uncleared yet. The current analysis aimed to evaluate the cost-effective of addin...
COVID-19-related hospitalizations in Italy: an application of the synthetic control method to investigate the trajectory of diagnosis related group 79 and its counterfactual during 2010-2021 [0.03%]
意大利与COVID-19相关的住院治疗：应用合成控制法在2010-2021年间探讨诊断相关组79及其反事实的轨迹变化
Carlo Lazzaro,Giovanni Fattore,Angelo Guido Corsico
Carlo Lazzaro
Background: with 10.95 million cases (11 March 2020-9 February 2022), Italy was massively hit by the coronavirus disease 2019 (COVID-19) pandemic. Most of the COVID-19-related inpatient discharges were codified under Diag...
Comparison of long-term overall survival with extrapolated overall survival for pembrolizumab assessed by Australian reimbursement authorities [0.03%]
澳大利亚药品报销评估机构对帕博利珠单抗长期OS与外推OS的对比分析
Francis C Dehle,Kevin Phan,Jerome Higgins et al.
Francis C Dehle et al.
Background: Decisions about government funding for new medicines often rely on statistical models to predict how long patients will live (overall survival, OS) based on early trial data. This study compared the accuracy o...
Matching-Adjusted Indirect Comparison and cost-effectiveness of mitoxantrone hydrochloride liposome versus Chidamide in relapsed or refractory peripheral T-Cell lymphoma in China [0.03%]
注射用紫杉醇聚合物结合型和西达本胺在治疗中国复发或难治性外周T细胞淋巴瘤的匹配调整间接对比及成本效果分析
Ying Liu,Xiaoning He
Ying Liu
Background: Mitoxantrone hydrochloride liposome (PLM60) is a novel liposome formulation, approved in China for the treatment of patients diagnosed with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This st...